Published in Eur J Nucl Med Mol Imaging on March 20, 2014
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA (2015) 1.57
The overlap between vascular disease and Alzheimer's disease--lessons from pathology. BMC Med (2014) 1.15
Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain (2015) 1.14
Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med (2015) 1.05
Post-mortem assessment in vascular dementia: advances and aspirations. BMC Med (2016) 0.98
Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther (2015) 0.87
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Front Neurosci (2015) 0.84
Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol (2015) 0.84
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology (2016) 0.79
Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice. Front Neurosci (2016) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement (2015) 0.78
Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease. Eur J Nucl Med Mol Imaging (2016) 0.77
Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay. Indian J Radiol Imaging (2016) 0.77
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res (2015) 0.77
Amyloid imaging for dementia in clinical practice. BMC Med (2015) 0.77
Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci (2015) 0.77
Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. J Cereb Blood Flow Metab (2015) 0.76
Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging (2015) 0.76
Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults. Front Aging Neurosci (2017) 0.75
Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients. Medicine (Baltimore) (2017) 0.75
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression. PLoS One (2016) 0.75
Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. J Alzheimers Dis (2016) 0.75
(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging (2017) 0.75
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement (2016) 0.75
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol (2012) 2.20
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med (2012) 2.16
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2011) 1.57
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med (2013) 1.26
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med (2012) 1.22
Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med (2009) 1.19
Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 1.15
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry (2012) 1.12
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA (2001) 10.63
Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med (2001) 7.14
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Positron emission tomographic studies of the cortical anatomy of single-word processing. Nature (1988) 6.90
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Contribution of anthropogenic and natural sources to atmospheric methane variability. Nature (2006) 5.66
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 5.12
Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med (2001) 4.73
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology (2007) 4.22
Mechanism of met oncogene activation. Cell (1986) 4.20
The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med (2001) 4.12
Excess fruit juice consumption by preschool-aged children is associated with short stature and obesity. Pediatrics (1997) 3.92
Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology (2007) 3.71
Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol (2000) 3.05
Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol (2000) 2.99
GroE facilitates refolding of citrate synthase by suppressing aggregation. Biochemistry (1991) 2.92
Longitudinal volumetric MRI change and rate of cognitive decline. Neurology (2005) 2.90
How practical are recommendations for dietary control in phenylketonuria? Lancet (2002) 2.82
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
White matter lesions impair frontal lobe function regardless of their location. Neurology (2004) 2.77
Protein conformational relaxation and ligand migration in myoglobin: a nanosecond to millisecond molecular movie from time-resolved Laue X-ray diffraction. Biochemistry (2001) 2.73
Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology (2000) 2.73
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology (2001) 2.69
Positron emission tomographic studies of the processing of singe words. J Cogn Neurosci (1989) 2.69
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology (2007) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA (2017) 2.58
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Context processing in older adults: evidence for a theory relating cognitive control to neurobiology in healthy aging. J Exp Psychol Gen (2001) 2.49
Enzymes for RNA sequence analysis. Preparation and specificity of exoplasmodial ribonucleases I and II from Physarum polycephalum. J Biol Chem (1978) 2.44
The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA (1999) 2.42
Common genetic variants influence human subcortical brain structures. Nature (2015) 2.40
Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer (2002) 2.38
Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance. Am J Psychiatry (1997) 2.37
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology (2002) 2.35
The process of metastasisation for breast cancer. Eur J Cancer (2003) 2.30
Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry (1998) 2.25
The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol (1999) 2.22
Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology (2005) 2.18
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A (1990) 2.11
MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology (2001) 2.11
Early infant mortality in West Germany before and after Chernobyl. Lancet (1989) 2.07
The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J Biol Chem (2001) 2.05
Facilitating networks of information. Proc AMIA Symp (2000) 2.05
A PC program for estimating organ dose and effective dose values in computed tomography. Eur Radiol (1999) 2.03
Extension of platelet shelf life from 4 to 5 days by implementation of a new screening strategy in Germany. Vox Sang (2011) 2.02
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012) 1.97
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
New gentamicin-resistance and lacZ promoter-probe cassettes suitable for insertion mutagenesis and generation of transcriptional fusions. Gene (1995) 1.94
Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology (2002) 1.91
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
Atrophy rates of entorhinal cortex in AD and normal aging. Neurology (2003) 1.88
Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med (1988) 1.87
The mycosubtilin synthetase of Bacillus subtilis ATCC6633: a multifunctional hybrid between a peptide synthetase, an amino transferase, and a fatty acid synthase. Proc Natl Acad Sci U S A (1999) 1.87
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal (2013) 1.85
Interference and facilitation effects during selective attention: an H215O PET study of Stroop task performance. Neuroimage (1995) 1.85
Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry (2005) 1.83
Coherent membrane supports for parallel microsynthesis and screening of bioactive peptides. Biopolymers (2000) 1.82
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol (2016) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology (2005) 1.70
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol (2001) 1.68
Sensitivity and specificity of a screening test to document traumatic experiences and to diagnose post-traumatic stress disorder in ARDS patients after intensive care treatment. Intensive Care Med (1999) 1.67
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology (2011) 1.66
Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol (1999) 1.66
Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology (2004) 1.64
Brain structure and cognition in a community sample of elderly Latinos. Neurology (2002) 1.62
Drug abuse in the United States Army. Bull N Y Acad Med (1971) 1.60
Physical mapping of new DNA probes near the fragile X mutation (FRAXA) by using a panel of cell lines. Am J Hum Genet (1990) 1.60
The use of malaria antibody tests in the prevention of transfusion-transmitted malaria. Vox Sang (2010) 1.60
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med (2000) 1.59
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer (2013) 1.57
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer (1996) 1.56
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Family of middle repetitive DNA sequences in the mouse genome with structural features of solitary retroviral long terminal repeats. Proc Natl Acad Sci U S A (1983) 1.54
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer (2001) 1.53
Incomplete X chromosome dosage compensation in chorionic villi of human placenta. Proc Natl Acad Sci U S A (1985) 1.53
Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J (1996) 1.53
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol (2000) 1.51
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol (2010) 1.49
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Allergens in Hymenoptera venoms. XXIII. Venom content of imported fire ant whole body extracts. Ann Allergy (1991) 1.48
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One (2013) 1.47
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46
Risk and outcome analysis of renal replacement therapies in patients after cardiac surgery with pre-operatively normal renal function. Anaesthesia (2009) 1.45
Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes (2006) 1.45